text_1: 90% of patients with melanoma and an objective response to PD-1 blockade will experience a progression in their melanoma.
text_2: Twelve-month progression-free survival rates were 35% (95% CI, 31%-39%) in the total population and 52% (95% CI, 43%-60%) among treatment-naive patients.